Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1993-12-9
|
| pubmed:abstractText |
The efficacy of the association of cisplatinum-mitomycine and vindesine on inoperable non-small cell bronchial cancer has been assessed in a prospective study. Cisplatinum 120 mg/m2 and mitomycine 8 mg/m2 on day 1, day 28 and day 70, and vindesine 3 mg/m2 once per week for the first cycle, once every 15 days for the second and third cycles. 98 patients were included in the study between February 1989 and June 1990: there were 89 men and 9 women with a mean age of 60. There were 57 epidermoid cancers, 22 adenocarcinomas, 1 neuroendocrine carcinoma and 18 large cell cancers. There was an objective response (RO) in 25% (of whom 5% had a complete response) without any significant difference between the 56 cancers at stage III (32% RO) and 42 cancers in stage IV (17% RO). The median survival of the responders was 14 months again 5 months for the non-responders. The initial loss of weight seemed to be a prognostic factor because the number of objective responders was significantly greater in the patients with only a small weight loss: 37% of RO if the weight loss was less than 5%, against 11% for a weight loss of greater than 5%. The myelotoxicity of this association was important because 85% of those patients presented with a leucopenia at least grade II OMS. Peripheral neuropathies occurred in 27% of cases: 4 cases of cardiotoxicity were reported.
|
| pubmed:commentsCorrections | |
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0761-8425
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
307-12
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7694331-Actuarial Analysis,
pubmed-meshheading:7694331-Aged,
pubmed-meshheading:7694331-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7694331-Carcinoma, Bronchogenic,
pubmed-meshheading:7694331-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:7694331-Cisplatin,
pubmed-meshheading:7694331-Female,
pubmed-meshheading:7694331-Heart Diseases,
pubmed-meshheading:7694331-Humans,
pubmed-meshheading:7694331-Leukopenia,
pubmed-meshheading:7694331-Lung Neoplasms,
pubmed-meshheading:7694331-Male,
pubmed-meshheading:7694331-Middle Aged,
pubmed-meshheading:7694331-Mitomycins,
pubmed-meshheading:7694331-Neoplasm Staging,
pubmed-meshheading:7694331-Palliative Care,
pubmed-meshheading:7694331-Peripheral Nervous System Diseases,
pubmed-meshheading:7694331-Prognosis,
pubmed-meshheading:7694331-Prospective Studies,
pubmed-meshheading:7694331-Remission Induction,
pubmed-meshheading:7694331-Survival Rate,
pubmed-meshheading:7694331-Vindesine,
pubmed-meshheading:7694331-Weight Loss
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
[Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology].
|
| pubmed:affiliation |
Département des Maladies Respiratoires, Hôpital Sainte-Marguerite, Marseille.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Review,
Multicenter Study
|